close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Galen Partners and Arena Capital Partners Complete Sale of EduNeering Holdings, Inc., to Kaplan, Inc.

PRINCETON, N.J., March 09, 2007 /PRNewswire/ -- Galen Partners and Arena Capital Partners are pleased to announce the completed sale of portfolio company EduNeering Holdings, Inc., to Kaplan, Inc. The transaction closed on March 6, 2007.

"EduNeering has grown from a small training company into an important provider of knowledge solutions to the healthcare, medical device, pharmaceutical and industrial sectors," said David W. Jahns, Managing Director with Galen Partners. "We are proud of our role in EduNeering's evolution and are pleased to see it become part of a company with Kaplan's reach and depth."

Arena Capital Partners' Steve McLean said, "Our investment partnership with Galen provided EduNeering with the financial resources to grow and diversify. We were confident in EduNeering's future and applaud its accomplishments."

EduNeering, a Deloitte Fast 500 Technology Company for the past three years, develops technology-enabled knowledge solutions for improving business performance and assuring regulatory compliance. EduNeering is recognized as a pioneer in the field of technology-based learning, counting among its clients many of the world's largest pharmaceutical and medical device companies, the U.S. Food and Drug Administration, and the National Institutes of Health.

Kaplan, Inc. is a leading international provider of educational and career services for individuals, schools and businesses. Kaplan, with 2005 revenue of more than $1.4 billion, is a subsidiary of The Washington Post Company .

Under terms of the acquisition, EduNeering will be renamed Kaplan EduNeering and will retain its current management team. It will join the Kaplan Professional division, a provider of education and compliance services in the fields of securities, insurance and real estate.

Robert W. Baird & Co. (www.rwbaird.com) acted as financial advisor to EduNeering on the transaction. Morgan, Lewis & Bockius LLP (www.morganlewis.com) provided legal counsel.

About Galen Partners (www.galen.com)

Galen Partners is a private equity firm, founded in 1990 and focused exclusively on providing equity financing to mid-to-later stage growth companies in the healthcare industry. With $648 million under management raised through four funds, Galen has invested in more than 60 companies. The firm emphasizes investments within medical device, technology-enabled outsourcing services and specialty pharmaceutical sectors. Over the past sixteen years, Galen Partners has been particularly adept at identifying, backing and developing future trend-setting, industry leaders including: Pyxis Corporation (a Cardinal Health company), Encore Medical Corporation, Lumenos, Inc. (a Wellpoint company), Ocular Sciences, Inc. (a CooperVision company), MiniMed, Inc. (a Medtronic company), Medicode, Inc. (a United Healthcare company), Stericycle, Inc. and MedAssets, Inc.

About Arena Capital Partners LLC (www.arenafund.com)

Arena Capital Partners is a private equity firm that invests in both established companies and developing businesses through structures including leveraged buyouts, structured preferred stock and common equity. The company's capital commitments range from $2 million to $25 million or greater in four targeted industries: education and training, information and financial services, consumer goods, and services.

CONTACT: Ellen Leinfuss of EduNeering Holdings, Inc., +1-609-627-5390

Web site: http://www.eduneering.com/http://www.rwbaird.com/http://www.galen.com/http://www.arenafund.com/

Ticker Symbol: (NYSE:WPO)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...